EVERSANA has acquired Estima Scientific, a London-based health economics and outcomes research technology and services company, expanding its AI-powered commercialization capabilities for pharmaceutical companies.
Estima Scientific will integrate its consulting expertise and proprietary software into EVERSANA’s market access and value and evidence solutions.
The company uses AI and automation to improve traditional health economics and outcomes research processes.
Estima has developed web-based generative AI applications incorporating proprietary code for economic modeling, systematic literature reviews, network meta-analysis, and other research functions.
EVERSANA said the acquisition supports its broader strategy of investing in technology-first businesses that can modernize pharmaceutical commercialization.
The company launched its AI Agency platform in 2025 and expanded it in August 2026, creating a foundation for additional AI-enabled products and services.
Estima Scientific’s team, including co-founders Tim Reason and Andy Gimblett, will join EVERSANA.
The transaction is intended to maintain continuity for Estima’s existing customers while giving the business access to EVERSANA’s global commercial infrastructure.
Estima’s technology has been used by large pharmaceutical companies and health technology assessment organizations, including the U.K.’s National Institute for Health and Care Excellence.
Founded in 2019, Estima combines health economics consulting with proprietary AI-powered software to help pharmaceutical and biotechnology companies demonstrate the clinical and economic value of therapies to payers and assessment bodies.
EVERSANA serves more than 650 organizations ranging from emerging biotechnology companies to established pharmaceutical businesses.
Bourne Partners served as exclusive financial advisor to Estima Scientific, while Wedlake Bell provided legal counsel.
The acquisition further expands EVERSANA’s capabilities in AI-enabled evidence generation and market access as pharmaceutical companies increasingly use automation to accelerate research and commercialization workflows.
KEY QUOTES:
“Today more than ever, the pharmaceutical industry must embrace AI to transform commercialization.”
Mark Thierer, CEO Of EVERSANA
“Joining EVERSANA is an incredible milestone for Estima Scientific and a validation of the specialized technology and consulting expertise our team has built.”
Tim Reason, Co-Founder Of Estima Scientific
